Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment

Infection

Volumn 34, Issue 4, 2006, Pages 190-195

  Wenisch, C ^a   Krause, R ^b   Szell M ^a   Laferl, H ^a  

^a Medizinische Abteilung mit Infektions und Tropenmedizin   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFIXIME; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; LEVOFLOXACIN; MOXIFLOXACIN;

ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENDER; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; ISCHEMIC HEART DISEASE; LETHALITY; MALE; MORTALITY; NURSING HOME; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; SMOKING; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BETA-LACTAMS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; MACROLIDES; MALE; MIDDLE AGED; OFLOXACIN; PNEUMONIA, BACTERIAL; QUINOLINES; TREATMENT FAILURE;

EID: 33747058801     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-006-5120-x     Document Type: Article

References (30)

1. Niederman MS, Mandell LA, Anzueto A. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
2. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-1433.
3. Feinsilver SH, Fein AM, Niederman MS, Schultz DE, Faegenburg DH. Utility of fiberoptic bronchoscopy in non-resolving pneumonia. Chest 1990; 98: 1322-1326.
4. Menéndez R, Perpiñá M, Torres A. Evaluation of nonresolving and progressive pneumonia. Semin Respir Infect 2003; 18: 103-111.
5. Genne D, Kaiser L, Kinge TN, Lew D. Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. Clin Microbiol Infect 2003; 9: 949-954.
6. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5 year prospective study. Rev Infect Dis 1989; 11: 586-589.
7. Ruiz M, Ewig S, Marcos MA. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397-405.
8. Malcolm C, Marrie TJ. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. Arch Intern Med 2003; 163: 797-802.
9. Fantin B, Aubert JP, Unger P, Lecoeur H, Carbon C. Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France. Chest 2001; 120: 185-192.
10. Minogue MF, Coley CM, Fine MJ, Marrie TJ, Kapoor W, Singer DE. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. Ann Emerg Med 1998; 31: 376-380.
11. Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with commmunity-acquired pneumonia. Arch Intern Med 2004; 164: 502-508.
12. Kuru T, Lynch JP. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999; 20: 623-651.
13. El-Solh AA, Aquilina AT, Gunen H, Ramadan F. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. J Am Geriatr Soc 2004; 52: 224-229.
14. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. Improving the appropriateness of hospital care in community-acquired pneumonia: a prediction rule to identify patients at low risk for mortality and other adverse outcomes. N Engl J Med 1997; 336: 243-250.
15. Massanari RM. Quality improvement: controlling the risks of adverse events. In: Wenzel RP (ed): Assessing quality health care. Williams & Wilkins, New York, 1992, p 201.
16. Frankl SE, Breeling JL, Goldman L. Preventability of emergent hospital readmission. Am J Med 1991; 90: 667-674.
17. Tan JS. Nonresponses and treatment failures with conventional empiric regimens in patients with community-acquired pneumonia. Infect Dis Clin North Am 2004; 18: 883-897.
18. Niederman MS, Bass JB, Campbell GD. Guidelines for the initial management of adults with community-acquired pneumonia. Am Rev Respir Dis 1993; 148: 1418-1421.
19. Arancibia F, Ewig S, Martinez JA. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162: 154-160.
20. Davey P, Rutherford D, Graham B, Lynch B, Malek M. Repeat consultations after antibiotic prescribing for respiratory infection: a study in one general practice. Br J Gen Pract 1994; 44: 509-513.
21. MacFarlane JT, Colville A, Guidon A, MacFarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 1993; 341: 511-514.
22. Fine MJ, Hough LJ, Medsger AR.The hospital admission decision for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997; 157: 36-44.
23. Waterer G, Somes G, Wunderink R. Monotherapy may be sub-optimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 16: 1837-1842.
24. Yu VL, Chiou CCC, Feldman C. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230-237.
25. Mortensen EM, Coley CM, Singer DE. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Outcome Research Team Cohort Study. Arch Intern Med 2002; 162: 1059-1064.
26. Waterer CW, Wunderink RG. Genetic susceptibility to pneumonia. Clin Chest Med. 2005; 26: 29-38.
27. File TM Jr, Tan JS. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides. Drugs 2003; 63: 181-205.
28. Rome L, Murali G, Lippmann M. Nonresolving pneumonia and mimics of pneumonia. Med Clin North Am 2001; 85: 1511-1530.
29. Buxbaum A, Straschil U, Moser C, Graninger W, Georgopoulos A. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network. J Antimicrob Chemother 1999; 43 (Suppl B): 13-18.
30. Feierl G, Marth E. Resistenzbericht 2004 der Medizinischen Universität Graz, 2005; pp 13-18, http://www.hygiene-graz.at/bakteriologie/ frameset.html accessed 14 July 2005.